WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has joined Accenture’s open partner ecosystem, designed to help solution providers, software vendors and life sciences companies team more effectively to accelerate drug discovery and improve patient outcomes.
The ecosystem is an integral part of Accenture’s cloud-based informatics research platform focused on improving productivity, efficiency and innovation in the drug discovery process. Accenture is currently working with a select number of independent software vendors and organizations, including PerkinElmer, to integrate their technology and content into Accenture’s research platform.
Joining the ecosystem is in sync with PerkinElmer’s strategy to deliver advanced informatics solutions that empower researchers to more quickly and easily spotlight key findings amidst the ever-growing volume, types and complexity of scientific big data.
PerkinElmer is making its informatics solutions compatible with Accenture’s integrated ecosystem starting with the following: key functionality of electronic laboratory notebooks, which allow for effective organization and sharing of experimental data; TIBCO® Spotfire® software for data visualization in research and clinical analytics; and ChemDraw® software, a leading application for chemistry-based analytics and workflows. PerkinElmer Signals™ solutions, which provide advanced analytics for R&D such as lead discovery and translational medicine, are also planned to be available via the Accenture ecosystem in the future.
“Today’s pharmaceutical companies are dealing with tremendous silos of data that are hard to access, expensive to maintain and can create missed opportunities to connect insights that propel new patient therapies,” said David Wang, general manager of Informatics at PerkinElmer. “Forward-looking life science organizations are reimagining, streamlining and accelerating the power of their research organizations by digitizing and integrating their big data. This is the promise of informatics in the lab, and we are pleased to be the largest instrument and informatics solution provider to join the Accenture ecosystem to date.”
“As PerkinElmer is a leading provider of lab instrument and informatics solutions, we’re pleased to welcome the company to Accenture’s open partner ecosystem and to be working closely with them to integrate their capabilities into our cloud-based research platform,” said Joe Donahue, a managing director in Accenture’s Life Sciences practice. “Our clients will benefit from access to PerkinElmer’s solutions and we look forward to collaborating with them to help our mutual clients gain insights from data to drive scientific discovery—ultimately improving patient outcomes.”
PerkinElmer at Bio-IT World 2019
In addition to sharing this
news at Bio-IT World Conference & Expo this week, PerkinElmer is also
exhibiting its Signals solutions at the event, as well presenting the
following sessions on Wednesday, April 17:
-
Leverage the Cancer Genome Atlas for Data Discovery in Oncology
Track 7; 12:00 p.m.
Location: Waterfront 1B/1C
-
Co-Presentation: Collaborating to Create a Better Screening Data
Process
Track 10; 5:15 p.m. (with Albany Molecular Research, Inc.)
Location: Cityview 1
For more information on PerkinElmer and its informatics solutions, please click here or visit booth #440 at the Seaport World Trade Center in Boston, April 16-18.
About PerkinElmer
PerkinElmer enables scientists,
researchers and clinicians to address their most critical challenges
across science and healthcare. With a mission focused on innovating for
a healthier world, we deliver unique solutions to serve the diagnostics,
life sciences, food and applied markets. We strategically partner with
customers to enable earlier and more accurate insights supported by deep
market knowledge and technical expertise. Our dedicated team of 12,500
employees worldwide is passionate about helping customers work to create
healthier families, improve the quality of life, and sustain the
wellbeing and longevity of people globally. The Company reported revenue
of approximately $2.8 billion in 2018, serves customers in more than 150
countries, and is a component of the S&P 500 index. Additional
information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
